Cost ManagementManagement has taken several steps to get itself back on track, including significant cost reductions and refocusing on its core optical genome mapping business.
Industry AdoptionA key driver is optical genome mapping gaining traction at leading institutions, seeing real-world use, and generating publications.
Market ValuationBionano shares are currently trading at an EV/Revenue multiple of 0.2x, which is less than one tenth of comparable companies’ average multiple of 3.5x.